Edinburgh and Cambridge, UK, 25 November 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.
Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology.
There is clear…
Creative Biolabs is rewriting the methods scientists use to develop binders and antibodies in the changing environment of therapeutic discovery. The company, which has a set of advanced platforms, is, therefore, a partner that many researchers can hardly do without as they go deeper into the most challenging molecular frontiers.From membrane proteins and post-translational modifications to elusive haptens and idiotypes, Creative Biolabs offers a rare combination of scientific depth and operational agility. "We don’t just screen—we engineer precision," noted one senior scientist at Creative…
Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Widely cited in recent published papers1, 2, 3, 4 - Detachin™ is proven to quickly deliver gentle detachment of a wide variety of adherent cells, including primary cell types and delicate culture systems, from any tissue culture plasticware. These papers involving primary immune cells, patient-derived cancer models, engineered mammalian lines and high-throughput screening systems, provide further…
Highly accomplished senior real estate executive leader and investment professional, Andy Creighton, joins Howard Group
Cambridge, 18th November 2025: Leading regional property investor and developer Howard Group, is delighted to announce the appointment of Andy Creighton as Group Property Director.
In his new role, Andy will be responsible for overseeing Howard Group’s property activities, including its investment, development and asset management functions. He will also be appointed to the Board of Directors and join the Executive Team.
Andy brings a long and…
LONDON, UK – November 19, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited (“Slingshot”) and is pleased to announce the placement of Dr. John Isaac as Chief Scientific Officer (CSO). Slingshot’s founding CSO Richard Wooster will now transition to a non-executive role as Scientific Advisor and Board member.Slingshot Therapeutics, the Syncona Accelerator, is a platform built to identify, de-risk and advance therapeutic…
Over four decades since its conception in 1980, Fragment-Based Drug Discovery (FBDD) has emerged as an innovative and efficient approach to modern drug development, showing advantages over traditional high-throughput screening (HTS) methods. By focusing on smaller, simpler molecules, FBDD provides a foundation for developing novel therapeutics, especially for challenging previously “undruggable” targets.
Historically, FBDD has led to several milestone achievements in drug development, with eight FDA-approved drugs and more than 50 compounds currently in clinical stages. The first FDA-…
Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.
Cambridge, UK – 19 November 2025 – Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
The collaboration brings together RxCelerate’s integrated drug discovery and development expertise with Constructive Bio’s proprietary…
The UK is set to give a unique second life to used nuclear materials. A £9.9m investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), backed by a further £8.9m from industry, will support a major project to develop cutting-edge new treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
These treatments are a type of precision medicine, known as radiopharmaceuticals. Whilst…
Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Cambridge, UK, 17 November 2025: Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Dr Stephen Shuttleworth as Chief Scientific…
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
Under the collaboration, Mursla Bio’s AI Precision Medicine…